

Supplemental Digital Content 2: Safety Endpoints

Study Number	V419-005, 006, 007, 008, and PRI01C	V419-004
Daily temperatures	Days 1 to 5	Days 1 to 7
Solicited injection-site AEs (pain/tenderness, erythema, swelling) and systemic AEs (vomiting, crying, somnolence, decreased appetite, irritability)	Days 1 to 5	Days 1 to 7
Unsolicited AEs	Days 1 to 15	Days 1 to 30
Serious AEs	up to 180 days after dose 3 and up to 14 days following the toddler dose in V419-005 and 006, up to 14 days after each dose in V419-007, V419-008 and PRI01C	throughout the study
Vaccine-related serious AEs and deaths	throughout the study	throughout the study